Health
Opaganib shows promise in preventing ARDS-induced thrombosis – Drug Target Review
Opaganib reduced blood clot length and weight in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
Posted: 16 December 2020 | Hannah Balfour (Drug Target Review) | No comments yet
Opaganib reduced blood clot length and weight in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
Opaganib (Yeliva®), a novel, orally administered sphingosine kinase 2 (SK2) selective inhibitor, (administered at 250mg/kg,) reduced thrombosis in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
According to the researchers, their findings suggest opaganib may be of benefit to patients…
-
General22 hours agoAustralian economy still vulnerable to US bond turmoil
-
Noosa News6 hours agoMotorbike rider dies after car collision at Kidaman Creek, west of Sunshine Coast
-
Business20 hours ago2 ASX 200 shares that could be top buys for growth
-
General7 hours agoDemocratic senators want an investigation into potential market manipulation from Trump’s inner circle